Study Finds Ruxolitinib Effective, Safe for Children With AD

There were no significant safety signals in the younger pediatric population, and 'no treatment-emergent adverse events suggestive of systemic JAK inhibition,' Dr Lawrence Eichenfield said.
MDedge News

source https://www.medscape.com/s/viewarticle/997954?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?